Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026)

Nuvalent (NUVL) posted Cash from Investing Activities of -$19.4 million for Q1 2026, up 93.09% on a QoQ basis from -$280.9 million in Q4 2025, and down 176.38% year-over-year from $25.4 million in Q1 2025.

Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026) Analysis & Trends

Nuvalent's Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$19.4 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 176.38% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$168.9 million (up 50.51% YoY) and the FY2025 annual result came in at -$124.1 million, up 78.37% from the prior year.
  • Cash from Investing Activities was -$19.4 million for Q1 2026 at Nuvalent, up from -$280.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $77.5 million in Q2 2025 and bottomed at -$280.9 million in Q4 2025.
  • A 5-year average of -$51.2 million and a median of $1.6 million in 2023 frame the typical range for Cash from Investing Activities.
  • Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 1074.65% — and 2024, when it soared 916.81%.
  • Nuvalent's Cash from Investing Activities stood at -$65.4 million in 2022, then climbed by 13.98% to -$56.3 million in 2023, then plunged by 202.24% to -$170.0 million in 2024, then slumped by 65.22% to -$280.9 million in 2025, then soared by 93.09% to -$19.4 million in 2026.
  • Business Quant data shows NUVL's Cash from Investing Activities at -$19.4 million in Q1 2026, -$280.9 million in Q4 2025, and $54.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 172.62 Mn
10 Nuvalent 9.75 Bn 9.75 Bn - -19.41 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -19.41 Mn
Mar 31, 2026 -19.41 Mn
Dec 31, 2025 -280.94 Mn
Dec 31, 2025 -280.94 Mn
Sep 30, 2025 53.97 Mn
Sep 30, 2025 53.97 Mn
Jun 30, 2025 77.48 Mn
Jun 30, 2025 77.48 Mn
Mar 31, 2025 25.42 Mn
Mar 31, 2025 25.42 Mn
Dec 31, 2024 -170.05 Mn
Dec 31, 2024 -170.05 Mn
Sep 30, 2024 -212.91 Mn
Sep 30, 2024 -212.91 Mn
Jun 30, 2024 16.21 Mn
Jun 30, 2024 16.21 Mn
Mar 31, 2024 -206.77 Mn
Mar 31, 2024 -206.77 Mn
Dec 31, 2023 -56.26 Mn
Dec 31, 2023 -56.26 Mn